$INGN

Yi Boyer Jennifer M sold $72K of INGN

Yi Boyer Jennifer M (EVP Entrprs Enblmnt, Ch HR Off) sold 10,938 shares of Inogen Inc (INGN) at $6.60 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yi Boyer Jennifer M
Published Jul 6, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INGN
Neutral
high confidence
Mentioned
$INGN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INGNNeutralLow
01

Why it matters

The disclosure quantifies the sale (10,938 shares at $6.5959) and confirms it was executed under a pre-arranged 10b5-1 plan, which typically lowers the likelihood of immediate fundamental implications.

02

Market read

Provides a concrete insider-selling datapoint for INGN, but without any new operational or guidance information.

03

What to watch

The filing does not indicate why shares were sold (taxes, diversification, scheduled liquidity), so the signal quality is limited.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction for Inogen, reported by an EVP and HR Chief Officer.

Company-level read

Ticker impact

$INGNNeutralHigh confidence
Context

Inogen Form 4 shows EVP Jennifer M Yi Boyer sold 10,938 shares on 2026-07-01 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is an SEC Form 4 insider transaction; it provides transaction details but no new company-specific operational or financial catalyst.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with perceived valuation risk; traders may still watch for follow-on selling.

Key entities

  • Inogen Inc

    Subject of the Form 4 insider transaction; EVP and HR Chief Officer sold shares under a 10b5-1 plan.

  • Yi Boyer Jennifer M

    EVP Entrprs Enblmnt, Ch HR Off; reported the open-market sale transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INGNMedAI 8/10

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

Inogen (NASDAQ:INGN) reported Q2 results with improving profitability and continued international growth, but weakness in the US oxygen rental and direct-to-consumer channels. International revenue was $41.3M (+15% YoY). US sales fell 2% to $42.3M and rental revenue dropped 12% to $11.6M. Full-year 2026 revenue guidance was cut to $355M-$361M.

$INGNMedAI 9/10

Inogen (INGN) Q2 2026 Earnings Call Transcript

Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.

$INGNMedAI 8/10

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Inogen (INGN) cut its 2026 revenue outlook to $355 million to $361 million from $366 million to $373 million after Q2 results showed ongoing U.S. channel pressure. Q2 U.S. sales fell 2.3% to $42.3M and U.S. rentals fell 11.8% to $11.6M, while international revenue rose 14.8% to $41.3M. Adjusted gross margin rose to 45.6%.

$INGNHigh

Inogen Inc (INGN): Results of Operations and Financial Condition

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN ), a medical technolog